Planned RCT to investigate GLP-1 RA therapy, exercise, and muscle mass in obesity.

Obesity management increasingly relies on Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which induce significant weight loss. However, a critical concern is the potential for these therapies to reduce skeletal muscle mass (SMM), a vital tissue for metabolic health, strength, and mobility. Current standard-of-care often overlooks strategies to mitigate this lean mass loss, leading to suboptimal functional outcomes. Furthermore, high rates of GLP-1 RA discontinuation within a year pose a risk of weight regain, with unknown impacts on physical and metabolic function post-cessation. This study addresses the critical gap in understanding how exercise can preserve SMM during GLP-1 RA therapy and the long-term effects of stopping treatment.